Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Adhera Therapeutics's shares outstanding for the quarter that ended in Sep. 2023 was 5.17 Mil.
Adhera Therapeutics's quarterly shares outstanding
increased
from Jun. 2023 (3.84 Mil) to Sep. 2023 (5.17 Mil).
It means Adhera Therapeuticsissued new shares from Jun. 2023 to Sep. 2023 .
Adhera Therapeutics's annual shares outstanding
increased
from Dec. 2021 (0.85 Mil) to Dec. 2022 (3.16 Mil).
It means Adhera Therapeuticsissued new shares from Dec. 2021 to Dec. 2022 .
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Adhera Therapeutics Shares Outstanding (EOP) Related Terms
Adhera Therapeutics Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for Adhera Therapeutics's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATRX vs PKBO, ARDS, NYMXF: Shares Outstanding (EOP) Comparison
For the Biotechnology subindustry, Adhera Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adhera Therapeutics Shares Outstanding (EOP) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adhera Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Adhera Therapeutics's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 5.17 Mil mean?
Adhera Therapeutics (ATRX) has a Shares Outstanding (EOP) of 5.17 Mil as of Sep. 2023. The total shares a company has outstanding, at period-end. View historical data on Adhera Therapeutics and its competitors.
Is Adhera Therapeutics' Shares Outstanding (EOP) too high?
Adhera Therapeutics' current Shares Outstanding (EOP) is 5.17 Mil. Overall, Adhera Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Adhera Therapeutics' Shares Outstanding (EOP) compare to PKBO and ARDS?
Adhera Therapeutics' Shares Outstanding (EOP) of 5.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Adhera Therapeutics and its competitors. Adhera Therapeutics's current Shares Outstanding (EOP) is 5.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adhera Therapeutics stock overvalued right now?
Adhera Therapeutics (ATRX) has a current Shares Outstanding (EOP) of 5.17 Mil. The current Shares Outstanding (EOP) is 5.17 Mil. Adhera Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Adhera Therapeutics (ATRX), the current Shares Outstanding (EOP) is 5.17 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adhera Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing advanced drug candidates through accelerated pathways. The company's pipeline includes MLR-1019 for Parkinson's disease and MLR-1023 for diabetes, both licensed from the Melior Discovery group. MLR-1019 (armesocarb) is a drug candidate targeting both movement and non-movement symptoms of Parkinson's disease, while MLR-1023 (tolimidone) is being developed for Type 1 diabetes and has undergone Phase 2a and 2b studies in Type 2 diabetes patients. It also explores additional drug development opportunities and maintains legacy assets such as CEQ508, an oral RNA therapy candidate for polyps associated with Familial Adenomatous Polyposis (FAP).
12GF Score
Get the complete analysis for ATRX
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATRX has been successfully added to your 
